Retatrutide Forschungspeptid – 99%+ Rein

Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and verified to >99% HPLC purity with a published batch Certificate of Analysis. View the batch Certificate of Analysis → Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a sealed 10-vial research pack , or add a single-vial laboratory sample alongside your pack to evaluate a compound at smaller scale first. Same source, same purity specification — scaled to whatever your research needs.

GLP1-RC-RT Certificate of Analysis

GLP1-RC-RT material is analysed by an independent laboratory, and the resulting Certificate of Analysis is published online. A certificate reports what was measured in the sample submitted; vials are not batch-marked, so it is not matched to a particular vial or order.

New-U GLP1-RC-RT certificate evidence

Catalogue identifier: GLP1-RC-RT

Independent testing laboratory, report number and test date

Measured purity for the sample analysed

Certificate of Analysis at /coa/retatrutide; the method and any identity result are stated on the report

Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Published scientific literature

External experimental and clinical studies

Receptor pharmacology and pharmacokinetics

Protocol-defined trial endpoints and timepoints

Adverse events recorded by investigators

Registered trial records and peer-reviewed citations (DOI / PMID / NCT)

Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-RT research material.

Veröffentlichte Forschungsbereiche

Veröffentlichte Studien untersuchen receptor activity, Pharmakokinetik und protokolldefinierte metabolische, hepatische und glykämische Endpunkte. Die Zusammenfassungen unten berichten, was Forschende in diesen externen Studien gemessen haben, und sind keine Anwendungsanweisungen für das hier bereitgestellte Forschungsmaterial.

Rezeptor-Pharmakologie

GLP-1R / GIPR / GCGR agonistische Aktivität, charakterisiert in veröffentlichten in-vitro-Rezeptorstudien.

Metabolische Endpunkte

Protokolldefinierte Veränderung der Körpermasse gegenüber dem Ausgangswert, gemessen in randomisierter klinischer Forschung.

Hepatische Endpunkte

Leberfettfraktion mittels MRI-PDFF, gemessen in einer randomisierten Phase 2a-Substudie.

Glykämische Endpunkte

HbA1c- und glucosebezogene Endpunkte als protokolldefinierte Endpunkte in klinischer Forschung

Pharmakokinetik

Systemische Exposition und scheinbare Eliminationshalbwertszeit aus veröffentlichter pharmakokinetischer Charakterisierung.

Scientific Overview

In short: GLP1-RC-RT ist ein triple GLP-1R / GIPR / GCGR agonist research compound, das in Forschungsgemeinschaften häufig als „Reta“ bezeichnet wird.

Key research facts

Rezeptor-Pharmakologie: agonistische Aktivität an GLP-1R, GIPR und GCGR in veröffentlichten in-vitro-Studien charakterisiert

In Rezeptor-Pharmakologiestudien wurde eine GIPR-Potenz von 8.9-fach gegenüber nativem GIP berichtet

Albuminbindende C20 fatty-diacid-Modifikation, untersucht als Beitrag zu verlängerter systemischer Exposition

Phase 2 obesity RCT (NEJM 2023, PMID 37385275): Forschende berichteten eine mittlere Veränderung des Körpergewichts gegenüber dem Ausgangswert von −24.2% in Woche 48 (12 mg arm)

Phase 3 TRIUMPH-1 (NCT05929066; sponsor-reported topline, ADA 2026; noch nicht peer-reviewed): Forschende berichteten eine mittlere Veränderung des Körpergewichts gegenüber dem Ausgangswert von −28.3% in Woche 80 (12 mg arm)

These points summarise lab themes, not human outcomes.

Veröffentlichte Arbeiten charakterisieren receptor pharmacology, strukturelle Modifikationen und das pharmakokinetische Profil dieser Verbindungsklasse, zusammen mit protokolldefinierten Endpunkten, die in präklinischer und registrierter klinischer Forschung untersucht werden.

Die Chargenverifizierung von New-U und die externe Literatur sind getrennte Evidenzgrundlagen: Die Chargenprüfung belegt analytische Identität und Reinheit des geprüften Materials; veröffentlichte Studien beschreiben ihre eigenen Prüfmaterialien und Protokolle.

Molekulare Architektur

Retatrutide (LY3437943) ist ein entwickeltes Peptid aus 39 Aminosäuren mit einem Molekulargewicht von 4,894.6 Da, das in receptor-pharmacology-Studien als Agonist an drei Rezeptoren charakterisiert wurde: GLP-1, GIP und glucagon. Das triple-receptor-Profil wird in der Literatur als „GGG“ tri-agonist bezeichnet.

Rezeptor-Pharmakologie

Berichtete EC50-Werte sind 0.775 nM an GLP-1R, 0.0643 nM an GIPR und 5.79 nM an GCGR, wobei die GIPR-Potenz als 8.9-fold gegenüber nativem GIP berichtet wird. Im Vergleich zur dualen GLP-1/GIP-Klasse ist der zusätzliche untersuchte Arm glucagon-receptor agonism; veröffentlichte Arbeiten untersuchen hepatic energy-expenditure-Endpunkte dieses Arms zusammen mit den für die Klasse insgesamt gemessenen incretin-Endpunkten. Vollständige Pfadtabelle: Mechanism of Action unten.

Strukturelle Modifikationen

Das GIP-derived backbone trägt Aib2- und Aib20-Substitutionen, die auf DPP-IV resistance untersucht werden, sowie α-methylleucine an Position 13, untersucht für protease stability. Eine über einen AEEA-γGlu spacer an Lys17 gebundene C20 fatty diacid wird als albumin-binding-Beitrag zu verlängerter systemischer Exposition untersucht.

Veröffentlichte Pharmakokinetik

Die scheinbare Eliminationshalbwertszeit wird unter den untersuchten Protokollen mit etwa 6 Tagen angegeben, bei hepatischem proteolytischem Metabolismus und ohne berichtete CYP-vermittelte Interaktion. Vollständiges pharmakokinetisches Profil: siehe Pharmacokinetics unten.

Präklinische & klinische Forschung

Die auf dieser Seite zusammengefassten veröffentlichten Befunde beziehen sich auf externe experimentelle und klinische Studien sowie deren jeweilige Prüfmaterialien und Protokolle. Sie belegen weder Sicherheit, Wirksamkeit noch klinische Gleichwertigkeit des New-U-Materials GLP1-RC-RT. Ergebnisse nach Studie: Forschungsbeobachtungen und Evidenzstufe unten.

Primärreferenzen

Peer-reviewed publications und der registrierte clinical-trial record für Retatrutide sind vollständig mit DOI/PMID/NCT-Identifikatoren in Source References unten aufgeführt.

At a glance

Mechanism and receptors Published experimental work characterises agonist activity across GLP-1R, GIPR and GCGR, with structural modifications investigated for proteolytic stability and prolonged systemic exposure.

Molecular characteristics Molecular weight 4,894.6 Da.

Pharmacokinetics Half-life: Apparent elimination half-life reported at approximately 6 days under the investigated protocols; steady-state exposure reported after 3–4 weeks.

Evidence maturity Tier 1: Human clinical — The evidence tier describes the published literature on Retatrutide, the scientific subject. Retatrutide remains investigational and is not approved in any jurisdiction.

Analytical verification Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Research limitations Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-RT research material.

Receptor Pharmacology

Published experimental work characterises agonist activity across GLP-1R, GIPR and GCGR, with structural modifications investigated for proteolytic stability and prolonged systemic exposure.

Pathway Effect Why it matters GLP-1R Agonist activity characterised in receptor pharmacology studies Reported EC50 0.775 nM; the receptor shared with the single- and dual-agonist reference compounds GIPR Agonist activity characterised experimentally Reported EC50 0.0643 nM; potency reported as 8.9-fold that of native GIP GCGR Agonist activity characterised experimentally Reported EC50 5.79 nM; the arm that distinguishes the triple agonist from dual GLP-1/GIP compounds in the literature Albumin-binding modification C20 fatty diacid via an AEEA-γGlu spacer Investigated as a contributor to prolonged systemic exposure (~6-day apparent half-life) Proteolytic stability Aib2, Aib20 and α-methylleucine-13 substitutions Structural modifications investigated for altered peptide stability against DPP-IV and protease cleavage

Deeper dive for scientific readers

Jastreboff et al. (N Engl J Med, 2023; PMID 37385275, DOI 10.1056/NEJMoa2301972) published the randomised Phase 2 obesity data: in the 12 mg arm investigators reported a mean change from baseline in body weight of −24.2% at week 48, with more than 90% of participants in that arm reaching a ≥10% reduction. Sanyal et al. (Nat Med, 2024; DOI 10.1038/s41591-024-03018-2) reported relative reductions in hepatic fat fraction of up to 82.4% in a Phase 2a MASLD population. The Phase 3 TRIUMPH-1 trial (NCT05929066) reported a mean change from baseline in body weight of −28.3% at week 80 in the 12 mg arm, with 45.3% of that arm reaching a ≥30% reduction — sponsor-reported topline, ADA 2026; not yet peer-reviewed. Published pharmacokinetic work reports hepatic proteolytic metabolism without CYP involvement and steady-state exposure after 3–4 weeks of the protocol-defined weekly administration. Every figure here is an observation recorded in the cited external study of the investigational compound.

Common Questions People Are Asking

Was ist GLP1-RC-RT?

GLP1-RC-RT ist die New-U-Katalogbezeichnung für dieses analytisch verifizierte research compound, das in Forschungsgemeinschaften häufig als „Reta“ bezeichnet wird. Es wird als Material für laboratory research bereitgestellt: Es ist kein Arzneimittel, keine Behandlung, kein generisches pharmazeutisches Produkt und kein therapeutisches Produkt, ist keinem klinischen oder kommerziellen Produkt gleichwertig und wird nicht für die Anwendung bei Menschen oder Tieren angeboten.

Welche Rezeptorsysteme wurden untersucht?

Veröffentlichte in-vitro-Pharmakologie charakterisiert Agonistenaktivität an drei Rezeptoren: GLP-1R (berichteter EC50 0.775 nM), GIPR (berichteter EC50 0.0643 nM, mit einer als 8.9-fold gegenüber nativem GIP berichteten Potenz) und GCGR (berichteter EC50 5.79 nM). Strukturelle Arbeiten untersuchen zusätzlich die C20 fatty-diacid albumin-binding-Modifikation als Beitrag zu verlängerter systemischer Exposition sowie Aib/α-methylleucine-Substitutionen für veränderte proteolytische Stabilität.

Welche analytischen Tests begleiten GLP1-RC-RT?

The published GLP1-RC-RT Certificate of Analysis comes from an independent analytical laboratory and records the independent laboratory, report number, measured purity and test date for the sample analysed; the method and any identity result are stated on the report itself. Vials are not batch-marked, so a certificate describes the sample tested rather than a particular vial or order. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Where can I view the current Certificate of Analysis for GLP1-RC-RT?

The current certificate — laboratory, report number, measured purity and test date — is published at /coa/retatrutide, together with the testing history for the compound. It is readable before ordering rather than on request afterwards.

Was bedeutet >99% HPLC purity?

Es handelt sich um einen Reinheitswert aus reversed-phase high-performance liquid chromatography mit area normalisation: Der Zielpeak macht mehr als 99% der gesamten integrierten Peakfläche im Chromatogramm der getesteten Probe aus. Dies ist ausschließlich eine Aussage über die chemische Reinheit dieser Probe. Der Wert beschreibt weder Sterilität noch Endotoxingehalt, Schwermetallgehalt, pharmazeutische Gleichwertigkeit oder irgendeine klinische Eigenschaft.

Auf welche klinischen Studien wird auf dieser Seite Bezug genommen?

Drei externe Studien zur investigational compound: die randomisierte Phase 2 obesity trial (Jastreboff et al., N Engl J Med 2023; PMID 37385275, DOI 10.1056/NEJMoa2301972), die Phase 2a MASLD trial (Sanyal et al., Nat Med 2024; DOI 10.1038/s41591-024-03018-2) und die Phase 3 TRIUMPH-1 trial (ClinicalTrials.gov NCT05929066). Jedes auf dieser Seite berichtete Ergebnis wird der jeweiligen Studie, dem Arm und dem Zeitpunkt zugeordnet. Die TRIUMPH-1-Zahlen sind sponsor-reported topline, bei ADA 2026 vorgestellt und noch nicht peer-reviewed; die Phase 2- und Phase 2a-Zahlen stammen aus peer-reviewed journal publications.

Wie wird veröffentlichte klinische Forschung von New-U Batch testing unterschieden?

They are separate bodies of evidence and this page keeps them apart. Published clinical research is external work on Retatrutide as an investigational compound, using those studies' own materials and protocols; it establishes nothing about the material supplied here. New-U certificate testing is analytical work on a submitted sample of the GLP1-RC-RT material: the published report states the measured result for the sample analysed, and it establishes nothing clinical. A certificate of analysis combined with an external clinical paper does not amount to clinical validation of GLP1-RC-RT.

In welcher Form wird GLP1-RC-RT bereitgestellt?

GLP1-RC-RT is supplied as a lyophilised powder in sealed vials, in single-vial laboratory samples and sealed 10-vial research packs across the listed strengths; the Certificate of Analysis is published on the product page.

Wie sollte Material für laboratory research gelagert werden?

Das lyophilisierte Pulver in einem Gefrierschrank bei −20 °C lagern. Wenn ein Laborprotokoll das Material in Lösung erfordert, die resultierende Lösung bei 1–6 °C gekühlt und lichtgeschützt halten und wiederholte freeze–thaw cycles vermeiden, die die fatty-acid-Modifikation abbauen können. Lagerbedingungen sind ausschließlich Informationen zur Laborhandhabung.

Wie unterscheidet sich dieses Rezeptorprofil von dualen und einzelnen Agonisten?

Die drei Klassen unterscheiden sich durch die Rezeptorabdeckung: Die semaglutide-Literatur beschreibt GLP-1R agonism, die tirzepatide-Literatur GIPR/GLP-1R agonism, und diese Verbindung wird auf GLP-1R/GIPR/GCGR agonism untersucht. Ihre klinischen Programme wurden getrennt durchgeführt, daher sind veröffentlichte Ergebnisse eines Programms keine head-to-head comparisons mit einem anderen.

Ist GLP1-RC-RT ein zugelassenes Arzneimittel?

Nein. Die zugehörige Verbindung ist investigational und wird in registrierten klinischen Studien untersucht; sie ist in keiner Rechtsordnung zugelassen. Das hier bereitgestellte Material ist laboratory research material und wird weder als Arzneimittel oder therapeutisches Produkt noch für Human- oder Veterinäranwendung angeboten.

Is it legal to buy Retatrutide?

In the United States, Retatrutide is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.

Research use only - all claims made on this site are for testing and research use only.

Pharmacokinetics

Half-life Apparent elimination half-life reported at approximately 6 days under the investigated protocols; steady-state exposure reported after 3–4 weeks Absorption route Study protocols used subcutaneous administration; reported Tmax 12–72 h with dose-proportional (linear) exposure Bioavailability High subcutaneous exposure with dose-proportional plasma levels reported Metabolism / clearance Hepatic proteolytic metabolism plus β-oxidation of the C20 fatty-diacid chain reported; no CYP-mediated interactions reported Stability Laboratory handling — lyophilised: −20 °C. Reconstituted: 1–6 °C, protect from light; avoid repeated freeze–thaw Notes The C20 fatty-diacid/albumin interaction is the protraction mechanism described in the published pharmacokinetic literature. These are pharmacokinetic observations from external studies of the investigational compound, not a handling or administration instruction for research material.

Research-Observed Effects

Phase 3 TRIUMPH-1 (NCT05929066), obesity/overweight population, 12 mg arm: investigators reported a mean change from baseline in body weight of −28.3% at week 80; 45.3% of that arm reached ≥30% reduction (sponsor-reported topline, ADA 2026; not yet peer-reviewed)

Phase 2 obesity RCT (Jastreboff et al., NEJM 2023; PMID 37385275), 12 mg arm: investigators reported a mean change from baseline in body weight of −24.2% at week 48, with >90% of that arm reaching ≥10% reduction

Phase 2a MASLD trial (Sanyal et al., Nat Med 2024): investigators reported relative hepatic fat-fraction reductions of up to 82.4% at the protocol-defined timepoint, with steatosis resolution reported in >90% of the 12 mg arm

Type 2 diabetes studies: investigators reported HbA1c reductions of 1.3–2.0% as a protocol-defined endpoint in the investigated arms

Experimental pharmacology: glucagon-receptor agonism is investigated in the literature as a contributor to hepatic energy-expenditure endpoints measured alongside the incretin endpoints

Published Research Context

Registered clinical research of the investigational compound used protocol-defined intervention arms. The Phase 2 programme included 1 mg, 4 mg, 8 mg and 12 mg arms; the Phase 3 TRIUMPH-1 trial randomised 4 mg, 9 mg and 12 mg arms against placebo. Study protocols used once-weekly subcutaneous administration with a protocol-defined step-up period of roughly 20–24 weeks before the maintenance arm level was reached.

These figures are characteristics of external clinical trials. They are recorded here as scientific study context and are not a protocol, schedule, starting point or instruction for any use of laboratory research material.

Adverse Events Reported in Published Clinical Research

The events below were recorded by investigators in published clinical trials of the investigational compound. They describe what was observed in those study populations under those protocols; they are not a prediction of, or guidance about, anything a reader may experience.

Common

Nausea — reported as the most frequent event, described as escalation-related and typically transient

Diarrhoea

Vomiting

Constipation

Decreased appetite recorded as a reported adverse event

Rare

Discontinuation due to adverse events, reported by arm in TRIUMPH-1: 4.1% (4 mg), 6.9% (9 mg), 11.3% (12 mg) vs 4.9% placebo

Transient increase in resting heart rate

Transient glucose elevation attributed to the glucagon-receptor arm, monitored under the study protocols

Dose-dependent

Investigators reported gastrointestinal events scaling with arm level and during the protocol-defined step-up period, attenuating at steady state

Higher arm levels were reported with both larger endpoint changes and a higher adverse-event discontinuation rate

Evidence Tier

Overall: Tier 1: Human clinical

The evidence tier describes the published literature on Retatrutide, the scientific subject. Retatrutide remains investigational and is not approved in any jurisdiction. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-RT research material.

Tier 1 · Human clinical

TRIUMPH-1 pivotal Phase 3 obesity RCT — −28.3% mean change from baseline in body weight at week 80 (NCT05929066; sponsor-reported topline, ADA 2026; not yet peer-reviewed)

Triple-agonist Phase 2 obesity RCT — −24.2% mean change from baseline at week 48 (NEJM 2023; PMID 37385275)

Phase 2a MASLD trial — up to 82.4% relative hepatic fat-fraction reduction (Nat Med 2024)

Certificates, databases & peer-reviewed sources

Last reviewed: 14 August 2026 · New-U Research Compounds

Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. · 2023 · PMID: 37385275 · DOI: 10.1056/NEJMoa2301972

Sanyal AJ et al. Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial. Nat Med. · 2024 · DOI: 10.1038/s41591-024-03018-2

TRIUMPH-1: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight - Phase 3 (Pivotal). ClinicalTrials.gov trial registration record. · 2023

Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Sponsor announcement (topline; not peer-reviewed), presented at ADA 86th Scientific Sessions. · 2026

Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide - A Game Changer in Obesity Pharmacotherapy. Biomolecules (review). · 2025 · PMID: 40563436 · DOI: 10.3390/biom15060796

PubMed: peer-reviewed literature on Retatrutide

ClinicalTrials.gov: registered studies on Retatrutide

Retatrutide: Wikipedia (search)

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

Engineered 39-amino-acid peptide (LY3437943)

Agonist activity characterised at GLP-1R, GIPR and GCGR in receptor-pharmacology studies

GIPR potency reported as 8.9-fold that of native GIP

C20 fatty-diacid albumin-binding modification investigated for prolonged systemic exposure

Apparent elimination half-life reported at approximately 6 days in published pharmacokinetic research

GLP1-RC-RT laboratory research material — analytically verified, >99% HPLC purity

Supplied as lyophilised powder for laboratory research; not an approved medicine

Specifications

New-U-Katalogidentifikator GLP1-RC-RT Wissenschaftliches Thema Retatrutide (LY3437943) Summenformel Komplexes Lipopeptid (C20 diacid-Konjugat) Molekulargewicht 4894.6 Da Rezeptoren charakterisiert GLP-1R (EC50 0.775 nM), GIPR (EC50 0.064 nM), GCGR (EC50 5.79 nM) Reinheit (analytisch) >99% mittels RP-HPLC-Flächennormalisierung Identität (analytisch) Stated on the published Certificate of Analysis where the report includes an identity test Form Lyophilisiertes Pulver Veröffentlichte Halbwertszeit Etwa 6 Tage (externe pharmakokinetische Forschung) Lagerung Lyophilisiert: −20 °C Gefrierschrank. Rekonstituiert: 1–6 °C, vor Licht geschützt. Vorgesehene Verwendung Laboratory research material. Not for human or veterinary use.

Retatrutide Research — GLP1-RC-RT Laboratory Research Material

Retatrutide (LY3437943) is investigated in the literature as the triple-receptor entrant in the incretin class. First-generation compounds such as semaglutide are characterised as GLP-1R agonists; dual compounds such as tirzepatide are characterised as GIPR/GLP-1R agonists; retatrutide adds glucagon-receptor agonism, which is why it is described as a "GGG" tri-agonist.

Published clinical research reports protocol-defined endpoints: a mean change from baseline in body weight of −24.2% at week 48 in the Phase 2 12 mg arm (NEJM 2023), −28.3% at week 80 in the Phase 3 TRIUMPH-1 12 mg arm (sponsor-reported topline, ADA 2026; not yet peer-reviewed), and relative hepatic fat-fraction reductions of up to 82.4% in a Phase 2a MASLD population (Nat Med 2024). Each of those figures belongs to the study that produced it, in the population and at the timepoint that study defined.

New-U Research Compounds supplies GLP1-RC-RT as lyophilised, analytically verified laboratory research material; its published independent Certificate of Analysis records the independent laboratory, report number, measured purity and test date for the sample analysed. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-RT research material. GLP1-RC-RT is not an approved medicine and is not offered for human or veterinary use.

Glucagon-like peptide-1 - Wikipedia

Gastric inhibitory polypeptide - Wikipedia

Glucagon - Wikipedia

Customer Reviews

Dobre śledzenie

Mogłem sam sprawdzać, gdzie jest przesyłka. Nie trzeba było dopytywać o każdy etap.

- Piotr Ś***** · 22 October 2026

Better checkout

I've used websites where the basket is a nightmare. This one was much easier to follow.

- aisha C***** · 20 October 2026

Comandă fără probleme - Retatrutide

Am găsit repede Retatrutide și am putut finaliza comanda fără bătăi de cap.

- Ramona M***** · 19 October 2026

More in Metabolic Research

Metabolic Research Semaglutide Semaglutide is a long-acting GLP-1 receptor agonist characterised in published research, with 94% homology to native human GLP-1 and a C18 fatty-diacid albumin-binding modification. GLP1-RC-SM is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Semaglutide →

Metabolic Research Tirzepatide Tirzepatide is a dual GIP / GLP-1 receptor agonist characterised in published research, with imbalanced agonism favouring GIPR. GLP1-RC-TZ is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Tirzepatide →

Metabolic Research Cagrilintide Cagrilintide (AM833), long-acting acylated amylin analogue and non-selective AMYR/CTR agonist with 8-day half-life for once-weekly obesity research. Cagrilintide →

Metabolic Research Eloralintide Eloralintide (LY3841136), a selective, long-acting amylin receptor agonist engineered for once-weekly subcutaneous obesity research, with AMY1R-preferring pharmacology. Eloralintide →

Metabolic Research Liraglutide Liraglutide is a GLP-1 receptor agonist: a 31-residue analogue of GLP-1(7-37) with an Arg34 substitution and a C16 palmitoyl-γ-glutamate side chain on Lys26 that promotes albumin binding. Liraglutide →

Retatrutide vs related Metabolic Research compounds

Compound Price Purity spec COA Retatrutide from $160 >99% HPLC 4 published batches Semaglutide from $106 >99% HPLC 1 published batch Tirzepatide from $168 >99% HPLC 2 published batches

Retatrutide vs Semaglutide - full comparison

Retatrutide vs Tirzepatide - full comparison

Descriptive catalog comparison for research sourcing decisions - not dosing guidance.

More on Retatrutide

Metabolic Research research compounds

Retatrutide research guide

Retatrutide pricing and packs

Research this compound

Research guide Retatrutide research guide Published experimental work characterises agonist activity across GLP-1R, GIPR and GCGR, with structural modifications investigated for… Read the guide →

Compare Compare Retatrutide and Liraglutide Retatrutide vs Liraglutide: mechanism, receptor profile and specifications side by side. Compare →

Analytical evidence View the Retatrutide COA Latest published certificate of analysis (purity and identity), dated 2026-07-24. View the COA →

Part of the Metabolic & GLP-1 research research area — explore related compounds, guides and sources.

From our community

What people say on Facebook

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research